Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
| 대상 질환 | FSGS |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | University of Colorado, Denver |
| 상태 | 완료 |
| 참여자 수 | 15 명 |
| 중재(약물) | Acthar |
| 시작일 | 2019년 2월 1일 |
| 완료일 | 2024년 6월 6일 |
| 결과 공개일 | 2020년 3월 24일 |
요약
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria
| One Arm | 14 Participants |
|---|
Rate of Recurrence of Proteinuria
| One Arm | 3 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida